Navigation

Search the NICE 'do not do' recommendations database

You can search the NICE 'do not do' recommendations database by:

  • typing in a specific term in the 'do not do' recommendations box
  • selecting an appropriate topic
  • selecting the type of source guidance.

To see the full list of all NICE 'do not do' recommendations leave all the fields blank and click the 'Search' button.

Urinary incontinence

Results 1-10 of 18

Guidance ID NICE 'do not do' recommendation Interventions
CG40 The use of multi-channel cystometry is not recommended before starting conservative treatment. multi-channel cystometry
CG40 For the small group of women with a clearly defined clinical diagnosis of pure stress urinary incontinence (UI), the use of multi-channel cystometry is not routinely recommended. multi-channel cystometry
CG40 Women who do not have symptoms of urinary tract infection (UTI) and whose urine tests negative for either leucocytes or nitrites are unlikely to have UTI and should not have a urine sample sent for culture. sending urine sample for culture
CG40 Pad tests are not recommended in the routine assessment of women with urinary incontinence (UI). pad tests
CG40 Electrical stimulation should not routinely be used in the treatment of women with overactive bladder syndrome (OAB). electrical stimulation
CG40 Electrical stimulation should not routinely be used in combination with pelvic floor muscle training. combination of electrical stimulation with pelvic floor muscle training
CG40 Propiverine should be considered as an option to treat frequency of urination in women with overactive bladder syndrome (OAB), but is not recommended for the treatment of urinary incontinenece (UI). propiverine
CG40 Flavoxate should not be used for the treatment of urinary (UI) or overactive bladder syndrome (OAB) in women. flavoxate
CG40 Duloxetine is not recommended as a first-line treatment for women with predominant stress UI. duloxetine
CG40 Systemic hormone replacement therapy is not recommended for the treatment of urinary incontinence (UI). systemic hormone replacement therapy

Back to ´do not do´ recommendations home

This page was last updated: 28 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.